A Phase IB, Open-Label, Multicenter Study to Investigate the Effect of Oral LBH589 [panobinostat] on Dextromethorphan, a CYP2D6 Substrate, and to Assess the Efficacy and Safety of Oral LBH589 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) or Malignant Pleural Mesothelioma.

Trial Profile

A Phase IB, Open-Label, Multicenter Study to Investigate the Effect of Oral LBH589 [panobinostat] on Dextromethorphan, a CYP2D6 Substrate, and to Assess the Efficacy and Safety of Oral LBH589 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) or Malignant Pleural Mesothelioma.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2012

At a glance

  • Drugs Dextromethorphan; Panobinostat
  • Indications Mesothelioma; Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 29 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 May 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 09 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top